Pfizer's need for deal looms larger with earnings report
July 28, 2014 at 01:36 AM EDT
NEW YORK (Reuters) - Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.
